Treatment modalities | N | % | HR (95%CI) |
---|---|---|---|
Surgery | |||
 Palliative | 16 | 11.10% | 2.915 (0.775–10.965) |
 Radical | 121 | 84% | ref |
 Conservative | 7 | 4.90% | |
Chemotherapy | |||
 Neoadjuvant | 6 | 4.20% | 1.667 (0.310–8.976) |
 Adjuvant | 98 | 68% | |
 Palliative | 23 | 16% | |
 No | 26 | 11.80% | ref |
Radiotherapy | |||
 No | 29 | 20.10% | 0.836 (0.321–2.1770 |
 Waiting list | 13 | 9% | |
 Yes | 102 | 70.80% | ref |
Hormonal therapy | |||
 Yes | 49 | 34% | ref |
 No | 8 | 5.60% | 1.04 (0.49–2.207) |
 HR-negative | 86 | 59.700% | |
Anti-HER2 therapy | |||
 HER2 positive | 44 | 30.60% |  |
 No | 26 | 18.10% | 0.844 (0.203–3.504) |
 Yes | 18 | 12.50% | ref |
Bisphosphonate treatment | |||
 Yes | 17 | 11.80% | N/A |
 No | 6 | 4.20% | N/A |
 Bone metastases | 23 | 16% |  |